BioSpace News Archive

Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostic technology, today announced the addition of two senior executives, each of whom will play a pivotal role in guiding the company toward its goal of delivering the first FDA-cleared non-invasive glucose monitor.

GelSight, a pioneer in tactile intelligence technology, announced the release of GelSight Mobile™ 2.4.

Halberd Corporation (OTC Pink: HALB) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine from a homogeneous mixture of two different cytokines in a fluid. Several adverse health conditions are caused by excess quantities of particular components in blood or cerebral spinal fluid (CSF), such as proteins, cytokines, amino acids, etc.

According to Vision Research Reports, the ePharmacy market size is expected to hit around US$ 209.2 billion by 2030 from valued at US$ 43.03 billion in 2020 and growing at a CAGR of 20.8% from 2021 to 2030.

According to Vision Research Reports, the Cell And Gene Therapy Clinical Trials market size is expected to hit around US$ 48.4 billion by 2030 and is anticipated to grow at a CAGR of 24.3% during forecast period 2021 to 2030.

The global clinical trial packaging market is expected to grow at a CAGR of 7.5% during the forecast period 2021 to 2030. The clinical trial packaging market is estimated to be driven by rising clinical trial activities coupled with rapid adoption of contract manufacturing in the pharma sector.

ZZ Biotech’s Stroke Drug Moves Closer to Pivotal Phase 3 Clinical Trial as the NIH Awards First Tranche of $30 Million Grant to the Keck School of Medicine of USC.

Benevira today announced positive preclinical safety and efficacy data on β521, a novel SARS-CoV-2 therapy, demonstrating robust tolerability and efficacy against several SARS-CoV-2 variants.

Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Dale MacCandlish Weil to its Board of Directors (Board).

Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced the appointment of Noubar Afeyan, Ph.D., co-founder and member of the board of directors of Rubius Therapeutics and chief executive officer of Flagship Pioneering, as chairman of its board of directors.